Polaris’ Amir Nashat pulls together a $60M launch round to back the birth of a new biotech building a drug development platform from scratch
Polaris Partners managing partner Amir Nashat has become a student of the role that biomolecular condensates play in shutting down or activating proteins. And he’s convinced that he’s found a door that opens on a long pathway to a new drug platform.
So convinced that he’s gathered a global syndicate together and packaged a $60 million launch round to back the 15 staffers at Dewpoint Therapeutics who have been assembled to start crafting a pipeline of new drugs from their work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.